This study is being conducted to directly characterize the pharmacokinetic (PK) profile of
plazomicin following administration of a single oral dose before and after IHD in subjects
with ESRD. This PK assessment will be used to provide appropriate plazomicin dosing
recommendations for patients with ESRD receiving IHD.